C
Curevo Vaccine
Creating Next Generation Vaccines For Diseases Of Global Importance
About Curevo Vaccine
Curevo Vaccine is a biotechnology company based in Seattle, specializing in the development of next-generation subunit vaccines for diseases of global health importance. The company’s lead vaccine candidate, CRV 101, is currently under investigation for its safety, tolerability, immunogenicity, and effectiveness in preventing Shingles in older adults. CRV 101 has successfully completed a Phase 1 clinical trial in healthy adults and is now being evaluated for its potential use in immunocompromised children to prevent chickenpox.
Read full description
Curevo Vaccine operates in the biotech sector, primarily serving healthcare providers, research institutions, and public health organizations. The company’s business model revolves around extensive research and development, clinical trials, and eventual commercialization of its vaccine candidates. Revenue is generated through partnerships, grants, and future sales of approved vaccines.
At a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 45.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Curevo Vaccine.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2026 | $0 | — | Eli Lilly | ↗ |
| SERIES BOther financing | Mar 2025 | $110M | $440M | RA Capital Management · Medicxi · OrbiMed · Janus Henderson Investors | ↗ |
Growth signals
Latest recorded traffic for Curevo Vaccine is 3.3K monthly website visits, up 0% over the last three months. Curevo Vaccine's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
RA Capital Management
Janus Henderson Investors
Adjuvant Capital- GPGC Pharma
- E&E&Investment
Medicxi
OrbiMed
Sanofi Ventures
HBM Healthcare Investments
Other known investors1 additional known investor
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Curevo Vaccine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Curevo Vaccine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.